When Essential Thrombocythemia Goes Triple-Negative: A Case of Acquired von Willebrand Disease
Author Information
Author(s): Muacevic Alexander, Adler John R, Kumar Sonal, Sabbagh Saad, Galili Yehuda, Carlan Steve
Primary Institution: Ross University School of Medicine, Cleveland Clinic Florida, Orlando Regional Medical Center
Hypothesis
What is the incidence of acquired von Willebrand disease in patients with triple-negative essential thrombocythemia?
Conclusion
The case demonstrates a successful response to treatment with aspirin and hydroxyurea in a patient with triple-negative essential thrombocythemia and acquired von Willebrand disease.
Supporting Evidence
- Acquired von Willebrand disease affects 10-20% of myeloproliferative neoplasm cases.
- The patient had a platelet count of 844 x 103/µL at presentation.
- Hydroxyurea treatment led to a significant decrease in platelet count.
- The resolution of acquired von Willebrand disease was observed after normalization of platelet levels.
Takeaway
This study is about a man with a rare blood condition who had very high platelet counts and a bleeding disorder, but he got better with medication.
Methodology
The patient was evaluated through clinical examination, laboratory tests, and treatment with hydroxyurea and aspirin.
Limitations
The study is based on a single case, limiting generalizability.
Participant Demographics
43-year-old male with a history of hyperlipidemia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website